SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study

Background: The potential benefits of intervention with empagliflozin or dapagliflozin for patients with heart failure with preserved ejection fraction (HFpEF) were first demonstrated in the EMPEROR-Preserved and DELIVER studies. However, the cost-effectiveness of this intervention (empagliflozin or...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, He, Shang, Pingping, Zhou, Dexing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525329/
https://www.ncbi.nlm.nih.gov/pubmed/37771722
http://dx.doi.org/10.3389/fphar.2023.1155210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525329/
https://www.ncbi.nlm.nih.gov/pubmed/37771722
http://dx.doi.org/10.3389/fphar.2023.1155210

Ejemplares similares